MedTrace Logo

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

NCT07099391 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2026-02-11

No results posted yet for this study

Summary

The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dexamethasone) is a safe treatment for people with newly diagnosed multiple myeloma (MM).

Conditions

Interventions

DRUG

Dara-RVd

This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy

DRUG

Tec-RVd

This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy

Sponsors & Collaborators

Principal Investigators

  • Neha Korde, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-24
Primary Completion
2029-07-24
Completion
2029-07-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07099391 on ClinicalTrials.gov